Cardiovascular Prostheses
Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.
1 . An implantable mesh construct for treating damaged biological tissue, comprising:
a mesh structure comprising a plurality of biodegradable fibers, each of said plurality of biodegradable fibers comprising an outer surface,
said plurality of biodegradable fibers comprising a first extracellular matrix (ECM) composition comprising first acellular ECM and a statin selected from the group consisting of atorvastatin, cerivastatin, lovastatin and simvastatin,
said mesh structure, when disposed proximate damaged biological tissue, being configured to modulate inflammation of said damaged biological tissue and induce cell and tissue proliferation, bioremodeling of said damaged biological tissue, and regeneration of new tissue structures with site-specific structural and functional properties when said mesh structure is disposed proximate said damaged tissue.
2 . The mesh construct of claim 1 , wherein said first acellular ECM is derived from a first decellularized mammalian tissue source selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), mesothelial tissue, placental tissue and cardiac tissue.
3 . The mesh construct of claim 1 , wherein said statin comprises cerivastatin.
4 . The mesh construct of claim 3 , wherein said inflammation modulation of said damaged biological tissue comprises restricted expression of monocyte chemoattractant protein-1 (MCP-1) and chemokine (C-C) motif ligand 2 (CCR2).
5 . The mesh construct of claim 1 , wherein said first ECM composition further comprises at least a first supplemental biologically active agent.
6 . The mesh construct of claim 5 , wherein said first supplemental biologically active agent comprises a first growth factor selected from the group consisting of transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), basic fibroblast growth factor (bFGF) and vascular epithelial growth factor (VEGF).
7 . The mesh construct of claim 5 , wherein said first supplemental biologically active agent comprises an exosome.
8 . The mesh construct of claim 1 , wherein said biomaterial composition further comprises a plurality of supplemental biologically active agents.
9 . The mesh construct of claim 8 , wherein said plurality of supplemental biologically active agents comprise agents selected from the group consisting of growth factors, cells and cytokines.
10 . The mesh construct of claim 9 , wherein at least one of said plurality of biodegradable fibers comprise a multi-stage agent delivery vehicle, wherein a modulated dosage of each of a first plurality of said plurality of supplemental biologically active agents is delivered to said damaged biological tissue when said mesh structure is disposed proximate said damaged biological tissue.
11 . The mesh construct of claim 1 , wherein said first ECM composition further comprises at least a first pharmacological agent.
12 . The mesh construct of claim 11 , wherein said first pharmacological agent comprises an agent selected from the group consisting of an antibiotic and anti-inflammatory.
13 . The mesh structure of claim 1 , wherein at least one of said plurality of biodegradable fibers comprises an outer coating, said outer coating being disposed on said outer surface of said at least one of said plurality of biodegradable fibers.
14 . The mesh structure of claim 13 , wherein said coating comprises a second ECM composition comprising a second acellular ECM derived from a second decellularized mammalian tissue source selected from the group consisting of SIS, UBS, UBM, LBM, SS, mesothelial tissue, placental tissue and cardiac tissue.
15 . The mesh structure of claim 14 , wherein said second acellular ECM composition coating further comprises at least one second supplemental biologically active agent.
16 . The mesh structure of claim 15 , wherein said second supplemental biologically active agent comprises a second growth factor selected from the group consisting of TGF-α, TGF-β, bFGF and VEGF.
17 . The mesh structure of claim 14 , wherein said second ECM composition coating further comprises at least a second pharmacological agent.
18 . The mesh structure of claim 17 , wherein said second pharmacological agent comprises a second agent selected from the group consisting of an anti-viral agent, antibiotic, anti-inflammatory, anticoagulant and vasodilating agent.
19 . The mesh structure of claim 13 , wherein said outer coating comprises a polymeric composition comprising at least one polymer selected from the group consisting of, polyglycolide (PGA), polylactide (PLA), polyepsilon-caprolactone (PCL), poly dioxanone (a polyether-ester), poly lactide-co-glycolide, polyamide esters, polyalkalene esters, polyvinyl esters, polyvinyl alcohol, and polyanhydrides.
20 . The mesh structure of claim 13 , wherein said outer coating comprises an ECM-mimicking biomaterial composition comprising poly(glycerol sebacate) (PGS).